Loading next page...
/lp/wiley/evolution-of-echocardiography-in-subclinical-detection-of-cancer-b7uVpj2TYq
- Publisher
- Wiley
- Copyright
- © 2018 Wiley Periodicals, Inc.
- ISSN
- 0742-2822
- eISSN
- 1540-8175
- DOI
- 10.1111/echo.14012
- pmid
- 29749652
- Publisher site
- See Article on Publisher Site
Abstract
Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction (CTRCD); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [LVEF]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging (TDI), and speckle tracking echocardiogram (STE) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities.
Journal
Echocardiography – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
Recommended Articles
Loading...
References
-
Cancer statistics, 2018Siegel, RL; Miller, KD; Jemal, A
-
Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyondMoudgil, R; Yeh, ET
-
Cardiac dysfunction in the trastuzumab clinical trials experienceSeidman, A; Hudis, C; Pierri, MK
-
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesYancy, CW; Jessup, M; Bozkurt, B
-
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapyThavendiranathan, P; Grant, AD; Negishi, T
-
Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapyCardinale, D; Colombo, A; Lamantia, G
-
Trastuzumab‐induced cardiotoxicity: clinical and prognostic implications of troponin I evaluationCardinale, D; Colombo, A; Torrisi, R
-
The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II‐positive breast cancer treated with adjuvant trastuzumab therapyFallah‐Rad, N; Walker, JR; Wassef, A
-
Trastuzumab‐related cardiotoxicity: calling into question the concept of reversibilityTelli, ML; Hunt, SA; Carlson, RW; Guardino, AE
-
Protective effects of carvedilol against anthracycline‐induced cardiomyopathyKalay, N; Basar, E; Ozdogru, I
-
Protective effects of nebivolol against anthracycline‐induced cardiomyopathy: a randomized control studyKaya, MG; Ozkan, M; Gunebakmaz, O
-
Cardioprotective effect of beta‐adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow‐up study of heart failureSeicean, S; Seicean, A; Alan, N; Plana, JC; Budd, GT; Marwick, TH
-
Prevention of high‐dose chemotherapy‐induced cardiotoxicity in high‐risk patients by angiotensin‐converting enzyme inhibitionCardinale, D; Colombo, A; Sandri, MT
-
Long‐term enalapril therapy for left ventricular dysfunction in doxorubicin‐treated survivors of childhood cancerLipshultz, SE; Lipsitz, SR; Sallan, SE
-
The effect of dexrazoxane on myocardial injury in doxorubicin‐treated children with acute lymphoblastic leukemiaLipshultz, SE; Rifai, N; Dalton, VM
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin‐treated children with high‐risk acute lymphoblastic leukaemia: long‐term follow‐up of a prospective, randomised, multicentre trialLipshultz, SE; Scully, RE; Lipsitz, SR
-
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site GroupSeymour, L; Bramwell, V; Moran, LA
-
ICRF‐187 permits longer treatment with doxorubicin in women with breast cancerSpeyer, JL; Green, MD; Zeleniuch‐Jacquotte, A
-
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewSwain, SM; Vici, P
-
Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin‐induced systolic dysfunction in humansStoddard, MF; Seeger, J; Liddell, NE; Hadley, TJ; Sullivan, DM; Kupersmith, J
-
Myocardial dysfunction late after low‐dose anthracycline treatment in asymptomatic pediatric patientsGaname, J; Claus, P; Uyttebroeck, A
-
Subclinical anthracycline‐ and trastuzumab‐induced cardiotoxicity in the long‐term follow‐up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic studyHo, E; Brown, A; Barrett, P
-
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective studyTassan‐Mangina, S; Codorean, D; Metivier, M
-
Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamicsMarchandise, B; Schroeder, E; Bosly, A
-
Ability of nonstrain diastolic parameters to predict doxorubicin‐induced cardiomyopathy: a systematic review with meta‐analysisNagiub, M; Nixon, JV; Kontos, MC
-
Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic functionDorup, I; Levitt, G; Sullivan, I; Sorensen, K
-
Cardiac diastolic function in pediatric patients receiving doxorubicinEwer, MS; Ali, MK; Gibbs, HR
-
Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhoodIarussi, D; Galderisi, M; Ratti, G
-
Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin‐treated patients and its correlation to conventional echo/Doppler indicesOcal, B; Oguz, D; Karademir, S
-
Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal studySorensen, K; Levitt, GA; Bull, C; Dorup, I; Sullivan, ID
-
Pulsed tissue Doppler illustrated to a resident in cardiologyGalderisi, M; Nistri, S; Ansalone, G
-
Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imagingGarcia, MJ; Rodriguez, L; Ares, M; Griffin, BP; Thomas, JD; Klein, AL
-
Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressuresNagueh, SF; Middleton, KJ; Kopelen, HA; Zoghbi, WA; Quiñones, MA
-
Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic functionSohn, DW; Chai, IH; Lee, DJ
-
Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclinesYagci‐Kupeli, B; Varan, A; Yorgun, H; Kaya, B; Büyükpamukçu, M
-
Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of EchocardiographyMor‐Avi, V; Lang, RM; Badano, LP
-
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long‐term observational study of outcome in 120 patientsJensen, BV; Skovsgaard, T; Nielsen, SL
-
Two‐dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapyStoodley, PW; Richards, DA; Hui, R
-
Echocardiographic assessment of myocardial strainGorcsan, J; Tanaka, H
-
Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancerJurcut, R; Wildiers, H; Ganame, J
-
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumabHare, JL; Brown, JK; Leano, R; Jenkins, C; Woodward, N; Marwick, TH
-
Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapyCheung, YF; Hong, WJ; Chan, GC; Wong, SJ; Ha, SY
-
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular ImagingPlana, JC; Galderisi, M; Barac, A
-
Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1Chang, HM; Moudgil, R; Scarabelli, T; Okwuosa, TM; Yeh, ETH
-
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesCurigliano, G; Cardinale, D; Suter, T
-
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyMaurea, N; Spallarossa, P; Cadeddu, C
-
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)Zamorano, JL; Lancellotti, P; Rodriguez Muñoz, D
-
Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapyVirani, SA; Dent, S; Brezden‐Masley, C
-
Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective studyMavinkurve‐Groothuis, AM; Marcus, KA; Pourier, M
-
Torsion analysis in the early detection of anthracycline‐mediated cardiomyopathyMotoki, H; Koyama, J; Nakazawa, H
-
Capecitabine‐related cardiotoxicity: recognition and managementSaif, MW; Tomita, M; Ledbetter, L; Diasio, RB
-
Early detection of anthracycline‐mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twistMornos, C; Petrescu, L
-
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular ImagingPlana, JC; Galderisi, M; Barac, A
-
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyMaurea, N; Spallarossa, P; Cadeddu, C
-
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)Zamorano, JL; Lancellotti, P; Rodriguez Munoz, D
-
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineRunowicz, CD; Leach, CR; Henry, NL
-
Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncologyGradishar, WJ; Anderson, BO; Balassanian, R
-
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelinesCurigliano, G; Cardinale, D; Suter, T
-
Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapyVirani, SA; Dent, S; Brezden‐Masley, C
-
Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1Chang, HM; Moudgil, R; Scarabelli, T; Okwuosa, TM; Yeh, ETH
-
Left ventricular twisting and untwisting motion in childhood cancer survivorsCheung, YF; Li, SN; Chan, GC; Wong, SJ; Ha, SY
-
Persistence, up to 18 months of follow‐up, of epirubicin‐induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markersMantovani, G; Madeddu, C; Cadeddu, C
-
Left ventricular function assessed by two‐dimensional speckle tracking echocardiography in long‐term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapyTsai, HR; Gjesdal, O; Wethal, T
-
Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fractionAljaroudi, W; Alraies, MC; Halley, C
-
Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle‐aged and elderly adults: the Strong Heart StudyBella, JN; Palmieri, V; Roman, MJ
-
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fractionDaugaard, G; Lassen, U; Bie, P
-
Mortality rate in patients with diastolic dysfunction and normal systolic functionHalley, CM; Houghtaling, PL; Khalil, MK; Thomas, JD; Jaber, WA
-
Cardiomyopathy with restrictive physiology in sickle cell diseaseNiss, O; Quinn, CT; Lane, A
@Phil_Robichaud
@deepthiw
@JoseServera